$90.73
0[0.00%]
At close: Apr 25
$90.73
0[0.00%]
PreMarket: 4:20PM EDT
Blueprint Medicines
(NASDAQ:BPMC)Latest News for Blueprint Medicines Stock (NASDAQ:BPMC)
Blueprint Medicines Stock (NASDAQ: BPMC)
Categories: All
Wednesday, April 10, 2024
Monday, February 26, 2024
Friday, February 23, 2024
Tuesday, February 20, 2024
Friday, February 16, 2024
Thursday, February 15, 2024
- Blueprint Medicines shares are trading higher after the company reported better-than-expected Q4 results.Benzinga Newsdesk - Feb 15, 2024, 10:44AM
- Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Feb 15, 2024, 10:23AM
- Blueprint Medicines Expects Global AYVAKIT Net Product Revenues Of Around $360M-$390M In 2024Benzinga Newsdesk - Feb 15, 2024, 7:06AM
- Blueprint Medicines Q4 EPS $(1.82) Beats $(2.04) Estimate, Sales $71.96M Beat $66.64M EstimateBenzinga Newsdesk - Feb 15, 2024, 7:04AM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Tuesday, January 16, 2024
Tuesday, January 09, 2024
- Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst InsightsBenzinga Insights - Jan 9, 2024, 10:00AM
- Stifel Maintains Buy on Blueprint Medicines, Raises Price Target to $97-Report Released on 8 January 2024Benzinga Newsdesk - Jan 9, 2024, 8:53AM
- Stifel Maintains Buy on Blueprint Medicines, Raises Price Target to $97Benzinga Newsdesk - Jan 9, 2024, 8:52AM
Friday, December 22, 2023
Tuesday, December 19, 2023
Tuesday, December 12, 2023
Monday, December 11, 2023
- Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Dec 11, 2023, 1:12PM
- Blueprint Medicines shares are trading higher after the company announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis.Benzinga Newsdesk - Dec 11, 2023, 11:38AM
- Reported December 9, 2023, Blueprint Medicines Announced Data Showcasing Its Commitment To Advance The Scientific Understanding And Treatment Of Systemic Mastocytosis Was Highlighted At 2023 ASH Annual MeetingBenzinga Newsdesk - Dec 11, 2023, 9:47AM
- The Latest Analyst Ratings for Blueprint MedicinesBenzinga Insights - Dec 11, 2023, 7:00AM
- HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $85 Price TargetBenzinga Newsdesk - Dec 11, 2023, 6:28AM
Friday, October 27, 2023
- Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To KnowBenzinga Insights - Oct 27, 2023, 1:00PM
- Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To KnowBenzinga Insights - Oct 27, 2023, 1:00PM
- Oppenheimer Upgrades Blueprint Medicines to Outperform, Announces $85 Price TargetBenzinga Newsdesk - Oct 27, 2023, 8:51AM
- Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $63Benzinga Newsdesk - Oct 27, 2023, 8:48AM
- Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $58Benzinga Newsdesk - Oct 27, 2023, 7:44AM
- Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $74Benzinga Newsdesk - Oct 27, 2023, 7:01AM
Thursday, October 26, 2023
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Oct 26, 2023, 1:31PM
- Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 26, 2023, 1:27PM
- IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On ThursdayLisa Levin - Oct 26, 2023, 11:55AM
- Blueprint Medicines shares are trading higher after the company reported better-than-expected Q3 financial results.Benzinga Newsdesk - Oct 26, 2023, 10:32AM
- Earnings Scheduled For October 26, 2023Benzinga Insights - Oct 26, 2023, 7:20AM
- Blueprint Medicines Q3 2023 EPS $(2.20) Beats $(2.37) Estimate, Revenues $56.6M Beat $50.4M EstimateBenzinga Newsdesk - Oct 26, 2023, 7:10AM
Wednesday, October 25, 2023
Monday, August 21, 2023
- Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales PredictionsVandana Singh - Aug 21, 2023, 3:23PM
- Analyst Ratings for Blueprint MedicinesBenzinga Insights - Aug 21, 2023, 10:00AM
- Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $66Benzinga Newsdesk - Aug 21, 2023, 6:03AM
Monday, August 07, 2023
Thursday, August 03, 2023
- Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $59Benzinga Newsdesk - Aug 3, 2023, 9:43AM
- Goldman Sachs Maintains Buy on Blueprint Medicines, Lowers Price Target to $83Benzinga Newsdesk - Aug 3, 2023, 8:50AM
- Needham Reiterates Buy on Blueprint Medicines, Maintains $65 Price TargetBenzinga Newsdesk - Aug 3, 2023, 7:05AM
- HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $85 Price TargetBenzinga Newsdesk - Aug 3, 2023, 6:27AM